More on ARCT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+87.8% Growth)
- Ratings (6.7 Score)
- Holders
- Dividends (7.3% Yield)

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcturus Therapeutics (NQ:ARCT)
Delayed: 9.84 -0.89 (8.29%)
Prev. Close $10.73  
Open$10.59 
52 Wk High$13.09 
52 Wk Low$5.54 
Day High$10.69 
Day Low$9.75 
P/E N/A  
EPS$-0.38 
Volume474,965 

Friends, Peers and Foes (?): ALNY, DNLI, OTLC SRPT (more...)

Oct 7, 2026 07:17 AM Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC.
Sep 24, 2026 07:17 AM Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald
Sep 24, 2026 05:40 AM Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG
Sep 24, 2026 02:44 AM Citi Upgrades Arcturus Therapeutics (ARCT) to Buy
Sep 23, 2026 04:12 PM Form 8-K Arcturus Therapeutics For: Sep 23
Sep 23, 2026 04:01 PM Arcturus shares Phase 2 OTC data, unveils new mRNA platform
Sep 23, 2026 04:01 PM Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Sep 18, 2026 09:00 AM Arcturus Therapeutics to present Phase 2 OTC deficiency data
Sep 18, 2026 09:00 AM Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Aug 25, 2026 06:05 AM Form 8-K Arcturus Therapeutics For: Aug 25
View All Articles

Entities mentioned with ARCT

View All Entities